Journal of Clinical Endocrinology & Metabolism, Vol 61, 580-584, Copyright © 1985 by Endocrine Society

ARTICLES

Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine

ML Vance, EC Ridgway and MO Thorner

Glycoprotein-secreting pituitary tumors are uncommon. With increased awareness that pituitary tumors may secrete FSH, LH, TSH, and the alpha- subunit, either as a sole product or in any combination, these tumors are more likely to be recognized. The standard therapy is surgical resection and, possibly, postoperative radiotherapy for residual tumor mass or persistent hormonal secretion. We report a patient with a FSH- and alpha-subunit-secreting tumor who refused surgery and was treated with the dopamine agonist bromocriptine as primary therapy. Bromocriptine treatment resulted in reduction of serum FSH and alpha- subunit levels to normal, improvement of visual field defects, and improvement in hypogonadism despite lack of demonstrable change in tumor size, as assessed by computed tomographic scan. Chromatographic analysis of the serum revealed distinct peaks corresponding to those of labeled FSH and alpha-subunit. The clinical and biochemical responses in this patient suggest that some glycoprotein-secreting tumors may be responsive to dopamine agonist therapy.

This article has been cited by other articles:

				A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, H. L J Tanghe, A.-J. van der Lely, and D. J Kwekkeboom Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? Eur. J. Endocrinol., November 1, 2006; 155(5): 717 - 723. [Abstract] [Full Text] [PDF]

				R. Pivonello, C. Matrone, M. Filippella, L. M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, and G. Lombardi Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1674 - 1683. [Abstract] [Full Text] [PDF]

				Y. Murata, H. Ando, T. Nagasaka, I. Takahashi, K. Saito, H. Fukugaki, K. Matsuzawa, and S. Mizutani Successful Pregnancy after Bromocriptine Therapy in an Anovulatory Woman Complicated with Ovarian Hyperstimulation Caused by Follicle-Stimulating Hormone-Producing Plurihormonal Pituitary Microadenoma J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1988 - 1993. [Abstract] [Full Text] [PDF]

				I. Shimon, T. Rubinek, I. Bar-Hava, D. Nass, M. Hadani, A. Amsterdam, and G. Harel Ovarian Hyperstimulation without Elevated Serum Estradiol Associated with Pure Follicle-Stimulating Hormone-Secreting Pituitary Adenoma J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3635 - 3640. [Abstract] [Full Text] [PDF]

				S. L. Asa, M. A. Kelly, D. K. Grandy, and M. J. Low Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice Endocrinology, November 1, 1999; 140(11): 5348 - 5355. [Abstract] [Full Text]